ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1542

A Re-evaluation of Global Financial Outlooks and Prospects in the Telehealth Industry Amidst the Transition to a Post-Pandemic Era

Arunkumar K
Regional manager, NJK Pharma

Abstract:- The onset of the COVID-19 pandemic propelled the telehealth sector into a period of rapid expansion, with web-based care emerging as a crucial tool for ensuring the safety of patients and healthcare providers alike. However, with the introduction of vaccines, the perceived need for telehealth services appeared to diminish, leading to a decline in value for telehealth companies. This shift prompted both existing players and newcomers in the telehealth space to innovate and redefine their value propositions in order to regain investor and customer confidence and stand out amidst increasing competition.

The struggle to reshape the perception of telehealth from a pandemic-era necessity to a valuable complement to traditional in-person care has been reflected in the volatility of stock prices and declining valuations. This dynamic has underscored the need for telehealth companies to differentiate themselves through technological advancements and the convenience they offer. Analyzing the market through qualitative secondary research, incorporating insights from contemporary sources, financial data from platforms like Yahoo! Finance, and peer-reviewed literature, it becomes evident that the telehealth market experienced a surge in 2020, reaching $17.9 billion in the US alone, and is projected to grow to $140.7 billion by 2030. This growth was accompanied by a nearly twofold increase in digital health venture funding, reaching $14.1 billion in total funding.

However, this rapid expansion led to an oversaturation of the market, with supply outpacing demand, resulting in a significant drop in valuations as vaccination rates rose in 2021. In response to this rebalancing, telehealth companies must chart a course for the post-pandemic era. The current role of suppliers in the telehealth space, whether they are established healthcare industry incumbents or innovative "telehealth-first" challengers, will influence the growth strategies they pursue. Moreover, identifying medical specialties and patient demographics that are best suited for web-based care will be critical for long-term success in the evolving healthcare delivery system. Looking ahead, investors should anticipate a bullish market characterized by growing share prices. Success in the telehealth industry is likely to hinge on fundamentally transforming care delivery models rather than simply transitioning traditional care to a web-based format. As the market consolidates, established telehealth giants capable of adapting to the changing landscape are expected to thrive, albeit amidst continued growth at a slower pace.

Keywords:- *Telehealth, Telemedicine, Remote Consultation, Web-Based Care, Web-Based Medicine.*

I. INTRODUCTION

During the chaos of the COVID-19 pandemic, the telehealth industry emerged as a crucial player in healthcare delivery, offering remote services via telecommunication and electronic transmission [1]. As the pandemic unfolded, patients and healthcare providers turned to telehealth to limit exposure, mirroring the shift to online work and education [2]. Unlike past outbreaks like SARS, COVID-19 propelled widespread adoption of telehealth [1]. The rapid uptake of telehealth during the pandemic sparked investor interest, injecting capital into a previously overlooked sector [3]. However, uncertainties arose regarding its post-vaccine sustainability. When eligibility restrictions for COVID-19 vaccines were lifted in May 2021, investors grew cautious, leading to a gradual decline in stock prices for major telehealth players [4]. This caution stemmed from doubts about telehealth's appeal once in-person care could safely resume. Yet, the pandemic revealed telehealth's potential beyond crisis response, showcasing its ability to complement or replace in-person care in certain scenarios [5,13]. However, without another crisis necessitating social distancing, telehealth's utilization is unlikely to match peak pandemic levels [2]. This realization prompted a market rebalancing, with stock values returning to more sustainable levels [4]. Our research, conducted from August 2021 to May 2023, draws on sources such as PubMed, Google Scholar, Bloomberg, and McKinsey. We define "telehealth" as the remote delivery of healthcare services via electronic means, including video calls, audio-only calls, and remote patient monitoring. Resilient telehealth companies will adapt to customer needs and innovate within the sector, paving the way for continued growth [3]. Despite market fluctuations, the long-term prospects for telehealth stocks remain optimistic, especially for companies well-positioned to leverage the benefits of remote healthcare delivery over traditional in-person care [4].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1542

II. TELEHEALTH: NAVIGATING A MARKET REALIGNMENT

The telehealth sector experienced remarkable growth during the COVID-19 pandemic, propelled by heightened demand for remote healthcare services. In 2019, the US telehealth market was valued at approximately US $11.23 billion, but by 2020, it surged to US $17.9 billion, representing a remarkable compound annual growth rate (CAGR) of 59.4% [4,5]. Moreover, digital health venture funding nearly doubled in 2020, reaching a total of US $14.1 billion, reflecting investor enthusiasm for telehealth [6].

However, with the introduction of COVID-19 vaccines and declining infection rates in 2021, stock prices for telehealth companies began to decline. Investors speculated that healthcare would revert to pre-pandemic norms, leading to a downward revision of the US telehealth market's CAGR to 22.9% for the period 2020-2030, projecting a market size of US $140.7 billion by 2030 [5].

Despite these declines, telehealth utilization remained significantly higher than pre-pandemic levels. Data from the United States Census Bureau's Household Pulse survey between April 2021 and August 2022 revealed that approximately 1 in 4 US adults had used telehealth services in the preceding 4 weeks [7]. Additionally, the Centers for Disease Control and Prevention reported that 37% of US adults had used telehealth services at least once in 2021 [8]. Patient and clinician satisfaction with telehealth remained high, with surveys indicating satisfaction rates of 91% for video consultations and 88% for telehealth's convenience compared to in-person visits [9,10].

Despite sustained demand, the financial outlook for telehealth appeared bleak due to overvaluation driven by pandemic-driven funding. For instance, Teladoc, a major telehealth company, experienced a significant decline in valuation post-pandemic, with its share price plummeting from US $293/share to US $26/share [11]. This trend mirrored the trajectory of EHR (Electronic Health Record) adoption following the implementation of the Affordable Care Act (ACA). The EHR industry experienced rapid growth, followed by a market rebalancing due to oversaturation. However, EHR adoption ultimately led to improved healthcare efficiency and interoperability [14].

The fluctuation in telehealth valuations may follow a similar pattern, with a rebalance indicating a shift towards more sustainable growth. While there are differences between EHR and telehealth technologies, the EHR valuation model offers insights into how industries experiencing rapid growth may undergo periods of adjustment before stabilizing [14]. Thus, despite short-term challenges, the long-term outlook for telehealth remains promising.

III. BARRIERS TO SUCCESS

- *Competitive Intensity:*

The rapid growth of the telehealth market during the pandemic has led to a proliferation of competitors, eroding the once-exclusive advantage of being a first mover. With numerous companies entering the market post-pandemic, such as Talkspace, GoodRx, and Amwell [19], competition has intensified, creating a crowded and saturated environment. Subsequently, weaker players may be forced out or acquired by stronger competitors due to their underwhelming financial performance relative to mid-pandemic valuations.

- *Cost Drivers:*

Telehealth companies must grapple with various cost drivers, including labor and reimbursement rates. Platforms employing clinicians directly, like Amwell and Teladoc, face the challenge of adjusting pricing to remain competitive, particularly as clinicians may migrate to platforms offering better compensation. In response, companies may resort to offering flexible pricing plans, as evidenced by Teladoc's adoption of per-member-per-month and per-subscriber plans to retain contracts [15]. Reducing costs and enhancing operational efficiency are paramount for the sustained viability of telehealth platforms [12,16].

Furthermore, coverage reductions by private payers are driving up costs for consumers, making it challenging for companies to offer affordable telehealth options, especially on a per-patient pay scale. Despite claims from direct-to-consumer companies about cost savings compared to in-person visits, potential hidden costs, such as subsequent in-person appointments or increased testing, may offset these savings. Additionally, the convenience of telehealth may lead to overutilization of services by patients, further complicating cost management[12,16].

- *Regulatory Risks and Barriers to Access:*

Telehealth companies must navigate shifting regulatory landscapes and variable reimbursement policies, posing significant risks to their operations. Regulatory uncertainty looms as governments contemplate rolling back pandemic-era regulations, such as waivers allowing telehealth provision outside rural areas and from patients' homes [18,19]. While some regulatory changes, like the expansion of reimbursable telehealth codes and the elimination of geographic restrictions for reimbursement, have been made permanent, others remain uncertain.

Moreover, addressing barriers to access, such as language barriers and connectivity issues, is crucial for ensuring equitable telehealth utilization. Underserved populations lacking Wi-Fi or video connectivity face challenges accessing telehealth services, exacerbating healthcare disparities. Technical issues, such as poor audio or image quality, also hinder the efficacy of telehealth visits, impacting provider satisfaction and patient outcomes [17,18].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1542

In conclusion, telehealth companies must navigate a complex landscape characterized by intense competition, cost pressures, and regulatory uncertainties to ensure sustainable growth and equitable access to healthcare services. Addressing these challenges requires innovative strategies and collaboration with stakeholders to overcome barriers and realize the full potential of telehealth in improving healthcare delivery.

IV. APPROACHES FOR CONTINUOUS ADOPTION AND MARKET EXPANSION

➢ *Identifying the Advantages of Telehealth*

In navigating the complexities of the telehealth industry, strategies for success must leverage the distinct advantages that telehealth offers over traditional care models. These advantages, such as increased accessibility to providers outside of regular office hours and access to specialized expertise not locally available, differentiate telehealth from in-person care. Moreover, the nature of the visit plays a significant role in determining the suitability of telehealth. Conditions that primarily involve discussions of symptoms, rather than requiring physical examinations or laboratory tests, are particularly well-suited for telehealth consultations. Understanding these advantages is essential for telehealth companies as they develop expansion strategies and target specific patient populations. Two primary approaches to expansion in the telehealth space are evident: web-based first and in-person first.

➢ *Web-Based First Expansion:*

Companies like Teladoc have adopted a web-based first approach, expanding their offerings beyond traditional telehealth consultations to include chronic care management. Despite initial market volatility, Teladoc's acquisition of Livongo enabled the company to enhance its chronic care capabilities, leading to sustained revenue growth [19]. This horizontal growth strategy involves diversifying product offerings across various medical specialties, akin to developing web-based "departments" for chronic care, primary care, and others.

➢ *In-Person First Expansion:*

Conversely, traditional healthcare companies are incorporating telehealth services into their existing portfolios through acquisitions and new service launches. For instance, CVS Health recently launched a web-based primary care offering, leveraging its extensive pharmacy and insurance network to provide round-the-clock care to members [20]. This vertical growth strategy involves expanding into new product areas, such as telehealth, while leveraging existing infrastructure and expertise.

➢ *Importance of Medical Specialty:*

Certain medical specialties are better suited for telehealth adoption than others. Analysis of patient visits during the pandemic revealed increased telehealth utilization in specialties such as psychiatry and endocrinology, while orthopedics saw minimal impact [21]. Chronic disease management, including conditions like diabetes and epilepsy, presents significant opportunities for remote care and monitoring. Studies have shown improvements in patient outcomes and satisfaction with telehealth interventions in these areas [22,23].

Additionally, telehealth has demonstrated promise in oncology, providing quality-of-life gains for patients and comparable clinical outcomes to traditional care [24,25]. While challenges exist, such as the need for physical examinations in some cases, telehealth offers valuable benefits, particularly for patients with rarer cancers who may face travel burdens to access specialized care [26,27]. Telehealth's advantages in accessibility, convenience, and suitability for certain medical specialties position it as a transformative force in healthcare delivery. Leveraging these advantages effectively, along with strategic expansion and targeted patient engagement, will be crucial for telehealth companies to realize their full potential in improving healthcare access and outcomes.

V. CONCLUSION

In conclusion, the telehealth sector has witnessed remarkable growth in recent years, fueled by low barriers to entry and the unprecedented market opportunities presented by the COVID-19 pandemic. However, as the pandemic's grip on in-person healthcare diminishes in the United States, the telehealth market faces new challenges. Competitive intensity, pricing pressures, and barriers to accessing care have emerged as significant hurdles for telehealth companies. To thrive in this evolving landscape, companies must understand the motivations of both patients and clinicians, focusing on factors such as cost, convenience, and efficacy. Merely transferring traditional care models to the internet is insufficient; instead, companies must innovate and develop integrative platforms that offer comprehensive telehealth solutions. For established healthcare giants, vertical expansion—incorporating telehealth services into existing in-person care offerings—may be the key to success. Conversely, newer telehealth businesses may find success through horizontal expansion, adding new services and indications to their existing web-based platforms.

Strategic acquisitions and expansions, particularly those targeting chronic illness management and psychiatric care, are likely to drive future growth in the telehealth sector. While valuations may have dipped in the short term, the market is undergoing a necessary rebalancing process. As telehealth companies adapt to the changing landscape and demonstrate their strategic value, investors may find renewed confidence in the sector. Looking ahead, telehealth remains a promising sector with potential for significant gains, particularly in light of future pandemics. By providing increased access to care and leveraging innovative technologies, telehealth stands poised to revolutionize healthcare delivery. As such, continued attention and investment in the telehealth industry are warranted.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/IJISRT24MAR1542

REFERENCES

[1]. Lewis W. Disaster response expert explains why the U.S. wasn't more prepared for the pandemic. *USC Dornsife College News.* 2020.

[2]. Growth Index of 9 Largest Telehealth Companies by Market Capitalization. *Thematic Capital.*

[3]. Largest telehealth companies by market cap. *CompaniesMarketCap.com.*

[4]. U.S. telehealth market size, share and trends analysis report by product type (hardware, software, services), by delivery mode (web-based, cloud-based, on-premises), by end use, and segment forecasts, 2022 - 2028. *Grand View Research.*

[5]. Telehealth market size, share and trends analysis report by product type (software, services), by delivery mode (cloud-based, web-based), by end-use (payers, patients), by disease area, by region, and segment forecasts, 2023 - 2030. *Grand View Research.*

[6]. DeSilva J, Zweig M, Doyle CE, Evans B, Goshay D, Prensky-Pomeranz R. 2020 market insights report: chasing a new equilibrium. *RockHealth.org.* 2021.

[7]. Lee EC, Grigorescu V, Enogieru I, Smith SR, Samson LW, Conmy A, De Lew N. Updated national survey trends in telehealth utilization and modality (2021-2022) *ASPE. Assistant Secretary for Planning and Evaluation. Office of Health Policy.* 2023.

[8]. Lucas JW, Villarroel MA. Telemedicine use among adults: United States, 2021. *Centers for Disease Control and Prevention.* 2022.

[9]. Pogorzelska K, Chlabicz S. Patient satisfaction with telemedicine during the COVID-19 pandemic-a systematic review. *Int J Environ Res Public Health.* 2022 May 17;19(10):6113. doi: 10.3390/ijerph19106113.

[10]. Hoff T, Lee DR. Physician satisfaction with telehealth: a systematic review and agenda for future research. *Qual Manag Health Care.* 2022;31(3):160–169. doi: 10.1097/QMH.0000000000000359.00019514-900000000-99938

[11]. Teladoc health's stock info. *Teladoc Health, Inc.*

[12]. Saju Thanislas. The Transformative Role of Telehealth in Hospital Environments Post-COVID: Enhancing Healthcare Delivery and Patient Outcomes, International Research Journal of Modernization in Engineering Technology and Science, Volume:05/Issue:09/September-2023, DOI : https://www.doi.org/10.56726/IRJMETS44599

[13]. Saju Thanislas. Cloud Migration Challenges for IP PBX in Critical Hospital Environments, International Journal of Advance Research, Ideas and Innovations in Technology, www.IJARIIT.com.

[14]. Conn J. Hospitals achieve 96% EHR adoption rate; data exchange still needs work. *Modern Healthcare.* 2016.

[15]. Annual report 2020. *Teladoc Health.* 2020.

[16]. Saju Thanislas, "Navigating the Future of Healthcare: Adapting to Transformative Changes in Care Delivery", International Journal of Creative Research Thoughts (IJCRT), ISSN:2320-2882, Volume.12, Issue 1, pp.g463-g475, January 2024, Available at :http://www.ijcrt.org/papers/IJCRT2401764.pdf

[17]. Jones P. U of M telehealth report finds disparities in access and similar productivity as in-person. *State of Reform.* 2021.

[18]. Saiyed S, Nguyen A, Singh R. Physician perspective and key satisfaction indicators with rapid telehealth adoption during the coronavirus disease 2019 pandemic. *Telemed J E Health.* 2021 Nov;27(11):1225–1234. doi: 10.1089/tmj.2020.0492.

[19]. Bakiny PJ. Is Teladoc stock a buy now? *The Motley Fool.* 2023. Apr 24.

[20]. Baxter A. CVS health launches new virtual primary care service. *Health Exec.* 2023.

[21]. Drake C, Lian T, Cameron B, Medynskaya K, Bosworth HB, Shah K. Understanding telemedicine's "New Normal": variations in telemedicine use by specialty line and patient demographics. *Telemed J E Health.* 2022 Jan;28(1):51–59. doi: 10.1089/tmj.2021.0041.

[22]. Boscari F, Ferretto S, Uliana A, Avogaro A, Bruttomesso D. Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown. *Nutr Diabetes.* 2021 Jan 05;11(1):1. doi: 10.1038/s41387-020-00147-8. doi: 10.1038/s41387-020-00147-8.10.1038/s41387-020-00147-8

[23]. Rasmusson KA, Hartshorn JC. A comparison of epilepsy patients in a traditional ambulatory clinic and a telemedicine clinic. *Epilepsia.* 2005 May;46(5):767–70. doi: 10.1111/j.1528-1167.2005.44804.x.

[24]. Larson JL, Rosen AB, Wilson FA. The effect of telehealth interventions on quality of life of cancer survivors: A systematic review and meta-analysis. *Health Informatics J.* 2020 Jun;26(2):1060–1078. doi: 10.1177/1460458219863604

[25]. Hsiehchen D, Muquith M, Haque W, Espinoza M, Yopp A, Beg MS. Clinical efficiency and safety outcomes of virtual care for oncology patients during the COVID-19 pandemic. *JCO Oncol Pract.* 2021 Sep;17(9):e1327–e1332. doi: 10.1200/OP.21.00092.

[26]. Sweeney NW, Goldsmith SR, Ahlstrom JM. Abstract 716: telehealth use among multiple myeloma patients during the COVID-19 pandemic. *Cancer Res.* 2021;81(13_Suppl):716. doi: 10.1158/1538-7445.AM2021-716

[27]. Smrke A, Younger E, Wilson R, Husson O, Farag S, Merry E, Macklin-Doherty A, Cojocaru E, Arthur A, Benson C, Miah AB, Zaidi S, Gennatas S, Jones RL. Telemedicine during the COVID-19 pandemic: impact on care for rare cancers. *JCO Glob Oncol.* 2020 Jul;6:1046–1051. doi: 10.1200/GO.20.00220. https://ascopubs.org/doi/10.1200/GO.20.00220